Haleos Labs Ltd

Dematerialisation status

• Dematerialisation requests processed; securities dematerialised during the period.
• Dematerialised securities listed on the stock exchanges where the prior issues were listed.
• Physical certificates mutilated and cancelled; depository registered owner substituted in records.

Haleos Labs Ltd - trading window closure

FDA Inspection Update

• US FDA inspection of Mahi Drugs Pvt Ltd, material subsidiary, Sept 15-18, 2026, found zero Form 483 observations.

AGM notice and email update

• AGM 20th of Haleos Labs is scheduled for 30 September 2026 at 3:00 pm via video conference.
• Notice and Annual Report 2025-26 will be circulated electronically to registered email addresses.
• Shareholders without registered emails must update via their DP/RTA.
• Record date for 2025-26 dividend is September 23, 2026; dividend payable within 30 days post-approval.
• EVEN 260907057 governs e-voting from September 26 to 29, 2026.
• Web links provided: Haleos site, NSE site, and evoting portal.
• KYC/email update contacts include Haleos and RTA: Aarthi Consultants.

AGM and investor information

• Haleos Labs to hold its 20th AGM on Sept 30, 2026 via VC/OAVM.
• FY2025-26 Annual Report and AGM notice dispatched electronically on Sept 8, 2026.
• Notice and Annual Report also available on Haleoslabs.com and stock exchange websites.
• Board recommends dividend of Rs 1.50 per share for FY2025-26, payable within 30 days of declaration.
• Unclaimed dividend and 2018-19 shares to be transferred to IEPF in 2026-27.
• Remote e-voting window from Sept 26 to Sept 29, 2026; cut-off date Sept 23, 2026.
• Scrutinizer for e-voting: Mr. C. Sudhir Babu.
• Special Window for relodgement of physical share transfers open until Feb 4, 2027.
• Participants must update KYC and bank details for dividend payments.

AGM Details

• Date and time: 30 September 2026 at 03:00 PM.
• Mode: VC/OAVM; deemed venue: Registered Office.
• First cut-off: 4 September 2026; second cut-off: 23 September 2026 for voting.

Ordinary Resolutions

• Adopt Audited standalone and consolidated financial statements for year ended 31 March 2026.
• Declare dividend on equity shares at ₹1.50 per share (15%).
• Re-appoint TVVSN Murthy as Director, retiring by rotation.
• Appoint M/s Suryanarayana & Suresh as Statutory Auditors for five-year term.

Special Resolutions

• Ratify remuneration payable to Cost Auditors for 2026-27: ₹75,000 plus taxes.
• Re-appoint Dr. Mannam Malakondaiah as Independent Director for second term.
• Re-appoint Dr. Srinivas Samavedam as Independent Director for second term.
• Approve revised MD remuneration from 1 October 2026 until expiry of tenure.

Financial highlights

• Standalone revenue from operations ₹300.99 Cr in 2025-26, down 9.71% YoY.
• Standalone EBITDA ₹41.89 Cr, down from ₹48.18 Cr prior year.
• Standalone PBT ₹25.19 Cr; PAT ₹17.78 Cr.
• Consolidated revenue ₹333.79 Cr; EBITDA ₹47.11 Cr; PAT ₹17.80 Cr.
• Standalone EPS ₹58.80; Dividend ₹1.50 per share for 2025-26.

Capital structure & liquidity

• Promoter shareholding 72.11%; public 27.89% as on 31-03-2026.
• General Reserve transferred ₹200 Lakhs; total General Reserve ₹7,616.02 Lakhs.
• Total borrowings (Standalone) ₹9,341.83 Lakhs; Net debt ₹9,301.94 Lakhs.
• Gearing ratio 0.43; cash and cash equivalents ₹39.89 Lakhs.
• Dividend payout: payment subject to tax; AGM approval required.

Operational & product developments

• Mahi Drugs Pvt Ltd revenue ₹59.02 Cr; net profit ₹1.22 Cr.
• US FDA inspection at Kazipally yielded VAI status; ANVISA no observations.
• Dorzolamide HCl validation completed; Brinzolamide in progress.
• Rebranding to Haleos Labs completed in Aug 2025.
• Expansion into regulated markets; focus on new products and collaborations.

Governance & board

• Board comprises seven directors; two Women directors.
• Sundaramma Patibandla resigned w.e.f. 29 May 2026.
• Independent Directors Mannam Malakondaiah and Srinivas Samavedam reappointed for second term from 13 Nov 2026.
• Remuneration for MD revised from 1 Oct 2026.

Audit, risk & compliance

• Statutory auditors: M/s Suryanarayana & Suresh appointed for 2026-27; AGM approval required.
• Secretarial auditors: SVVS & Associates; no qualifications reported.
• Management and board affirm internal controls and no fraud reported.
• Independent directors affirm compliance with applicable governance norms.

CSR & ESG

• CSR spent ₹44.25 Lakhs; 2% obligation ₹43.23 Lakhs; carry forward ₹1.02 Lakhs.
• CSR projects include road construction at Kazipally and GHMC building in Patancheru.
• CSR policy and projects disclosure on company website.

Outlook & risks

• Strategy emphasises portfolio diversification, regulated markets, and contract manufacturing growth.
• Risks include pricing pressures, raw material costs, logistics, and regulatory changes.

Res 1: WTD reappointment

• Special resolution; passed; WTD reappointment; In favour 117,023; Against 15; Invalid 483,612.

Res 2: ED remuneration

• Special resolution; not passed; ED remuneration; In favour 107,148; Against 493,502.

Res 3: Company RPTs 2026-27

• Ordinary resolution; passed; Company RPTs for 2026-27; In favour 117,023; Against 0.

Res 4: Subsidiary RPTs 2026-27

• Ordinary resolution; passed; Subsidiary RPTs for 2026-27; In favour 117,022; Against 16.

Dividend and TDS update

• Board recommends final dividend of ₹1.50 per share (15%) for FY2025-26, subject to AGM approval.
• Record date: 23 September 2026; dividend paid electronically to shareholders with registered bank details.
• Dividend tax deducted at source; TDS rates depend on shareholder category; submit required documents by 25 September 2026.
• Shareholders to update PAN, address, and category with DP/RTA; documents via RTA portal by 25 Sept 2026.
• Non-resident/DTAA options: 20% TDS for certain categories; TRC and Form 41E required to claim benefits.
• Note: communications to shareholders to registered email; late submissions after 25 Sept 2026 not considered.

Q1 2026 results & publication

• Subject: Publication of Q1 2026 unaudited consolidated results.
• Consolidated revenue for quarter: ₹7,294.23 lakhs; PAT: ₹184.03 lakhs; EPS: ₹8.75.
• Standalone revenue: ₹6,782.97 lakhs; PAT: ₹323.78 lakhs.
• Audit Committee reviewed and Board approved results on 05.08.2026.
• Results filed with exchanges under Regulation 33 of SEBI LODR.
• Newspaper advertisements published August 7, 2026.
• Special window for re-lodgement of physical share transfers open till 04.02.2027.
• Full results accessible on HaleosLabs.com and stock exchange websites.
• Publications appeared in Business Standard (English) and Telugu Prabha (Telugu).
• Reporting period: quarter ended 30 June 2026.